A B S T R A C T Endogeniouis release of epiinephlrine alter stress as well as exogenouis epinephrine infusion are known to resuilt in imiipaired glucose tolerance. Previouis stuidies of man and animals have demonoestrated that this effect of epinephrine results fromn inhibitioni of insulin secretion and aiugiimentation of hepatic glucose production. However, the effect of epiniephrine oii tissue sensitivity to insulin, and the relative contribuitions of peripheral vs. hepatic resistanice to imnpairedl insulin action, have not l)een defined. Nine young normal-weight stubjects were sttuldied with the insuilin clamp technique. Plasma insuilin was raised by -100 gU/nil wilie plasiiia glticose conicentrationi Wcas Imlainitaine(d at basal levels by a variable glucose infuision. Under these conditions of euglycemiiia, the amnouniit of glucose metabolized e(quals the glucose inftusion rate ancd is a measure of tissue sensitivity to insulin. Sulbjects receive(l four studies: (a) insulini (42.6 mlU/in2 -min), (b) insulini plus epiniephrine (0.05 ,ug/kgmniin), (c) insulimi pltus epinephrine plus propranolol (1.43 ,ug/kg mmii), and ((d) insulin pltus propra<nolol. Duiring insulin admllinistrationi alonie, glucose metabolism averaged 5.49±+(0.58 mng/kg mmin. W'heni epinephrine was inftused with insuilin, glucose miietabolism fell by 41% to 3.26 ing/kg miin (P < 0.001). After instulini alone, hepatic glucose produiction declined by 92% to 0.16±0.08 nmg/kg mmin. Addition of epinephrine xwas associated witlh a delayed aind iniconplete suippression of glucose pro(luction (P < 0.01) despite plasmia insulin levels >100 ,TU/mI,1. Wlheni propranolol svis admlliinistered witlh epiniephrine, total glucose mnetabolism wvas restored to cotntrol values and hepatic glucose production suippressed normally. Propranolol alone had no effect on1 iusulin-mediated gltucose metabolism. Thlese results indicate that epinephrine, acting primarilx througl a fl-adrenergic receptor, mlarkedly imnpairs tisstie sensitivity to ani inecrease in plasmiia instulini levels, and( that this effect results fromn both peripheral and hepatic resistance to the actiomi of insulin.
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Received for publication 21 Attemi-pts to categorize the metalbolic effects of epinephrine as either alpla (a) or-beta (,f) receptorme(liate(l have yielded contradlictorv results. It hslS been reported that neither a-nor 8-blockade alone is sufficienit to prevent the hyperglycem-lic effect of epinephiine inifusion in normiiial mnan, buIt that coml)inedl p)ropranolol and phentolamine pretreatmiient alolishes the hy'perglycemnic effect of epinephrinie infuLisioni (15) . In dialbetic suibjects (16) (12, 14) .
In the present stmm(ly we halve employed the euiglycemic iiistulinl clamp technlilqe in comnl)inationi witl tritiated glucose to (ju.iantitate the effect of epinephrine on tissue sensitivity to insu1lin, anid to definie the rellative contributions of p)eril)lperal vs. hepeatic resistamLice to the actioni of inlsuiliin. WTe halve atlso (lemi)onistrated that the effects of epineplhrine On both hepatic amid periplheral gluicose mnetabolism are miiediacted primarily via the 8-adrenergic receptor.
METHODS
Subjects. The study group consisted of nine healthy volunteers (five females and four males) ranging in age from 23 to 30 yr (mean±SEM = 26+1 yr), and in ideal body weight (based on Metropolitan Life Insurance tables, 1959) from 90 to 112% of the normial (mean = 99+2%). All subjects were consumiiiing a weight-maintaining diet containing at least 200 g of carbohydrate/d for at least 3 d before study. No subjects consumied any medications during the 4 wk before study. Each subject served as his own control. All stuidies were carried out in the postabsorptive state at 8 a.m. after a 12-h overnight fast. The purpose and potential risks of the study were explained to each subject; written voluntary consent was obtained before participation.
Insuilin clamp) studies. Tissuie sensitivity to insulin was determined by the insulin clamp technique as described (17) . After a 120-min control period to allow for equilibration of [3-3H] glucose (18) , a priming plus continuous infusion of crystalline procine insulin (Eli Lilly & Co., Indianapolis, Ind.) was administered to obtain constant physiological hyperinsulinemia. The priming dose was administered in a logarithmically falling manner over 10 min, at which time the continuous infusion was initiated. The continuous insulin infusion was given at a rate of 42.6 mU/in2 surface area per min anid was maintained for 110 min. The plasma glucose was maintained at basal preinfusion levels by the determination of plasma glucose concentration every 5 min and the periodic adjustment of a variable infusion of 20% glucose solution (17) . Under these steady-state conditions of constant euglycemnia, all ofthe glucose infused was taken up by the cells.
Each subject subsequently tunderwent a repeat insulin clamp study with the infusion of epinephrine. The procedure was identical to that outlinied above except that a constant infusion of epinephrine at a rate of 0.05 ,ug/kg body wt per inin was initiated simultaneously with the infusion of insulin. The epinephrine infusate (Parke-Davis Co., Detroit, Mich.) was prepared with normal saline and the addition of ascorbic acid, 1.0 mg/lml of infusate, to prevent autooxidationi.
Each subject underwent a third insulin clamiip study during which propranolol was infused with epinephrine. The propranolol (Inderal, Ayerst Laboratories, New York.) was administered as a priming dose of 0.001 mg/kg body weight per minute during the 5 min preceding the initiation of insulin infusion. The propranolol infusion was then continued at a rate of 0.001 mg/kg min in concert with the infusion of epinephrine at a rate of 0.05 gg/kg body wt per min for the ensuing 120 min of the insulin clamp proceduire.
Finally, each subject underwent an insulin clamp during which propranolol alone was infused. The propranolol was administered as a prime-continuous infusion as described above.
CalcuIlatiotns. During the insulin clamp studies, the glucose infusion rate was determined by calculating the mean value observed during selected time intervals. Total glucose metabolismn during a given time period was calculated by adding the mean rate of endogenous glucose production during that time period to the imean glucose infusion rate during the samne time period. To calculate the steady-state plasma glucose and insulin concentrations during the insulin infusion, the mean values from 20 to 120 min were employed. The metabolic clearance rate of insulin was calculated by dividing the continuious insulin infusion rate (42.6 mU/in2 imin) by the mean increment above basal in plasma insulin concentration during the 20-120 min time period.
After the initiation ofthe insulin-glucose infusion during the insulin clamp procedures, glucose production in the basal state was determined as described (17) . The rate of endogenous glucose production was calculated by subtracting the glucose infusion rate from the rate of glucose appearance as determined with tritiated glucose. (19) , and tritiated plasma gltucose specific activity (18) have been described previously. Plasma epinephrine levels were determined by Dr. Rosa Hendler emiploying a radioenzymatic assay (20) .
RESULTS
Plasma glucose, insulin, glucagon, and epinephrine concentration (Table I) . Mean steady-state plasma insulin concentrations were maintained at -132-135 ,uU/ml during all four insulin clamp studies. During all studies the plasmna glucose was held close to the basal level. The stability of the plasma insulin and glucose levels is indicated by the small coefficients of variation. The metabolic clearance rate of insulin averaged 361±12 m1/m2 min during the control study and was unchanged by epinephrine (361±16 ml/rn'2 nin), epinephrine and propranolol (364±12 ml/m'l min), or propranolol alone (370±14 mIl/M2. min). Plasma glucagon concentration fell slightly during the control insulin clamp study (P < 0.05) and was unchanged when epinephrine was infused with insulin. During both clamp studies in which propranolol was infused, the decline in plasma glucagon was similar to the control insulin clamp study (P < 0.05). Fasting plasma epinephrine levels were similar during all four studies and were unchanged during the control insulin clamp study or by the infusion of propranolol alone. When epinephrine alone was infused, the mean plasma epinephrine level during the 60-120 min time period was 736±23 pg/ml. When propranolol was infused with epinephrine, the mean plasma epinephrine concentration was significantly higher than with epinephrine alone, 1,441±96 pg/ml (P < 0.001).
Glucose metabolismn (Tables II and III) . During the basal state the rate of glucose metabolism by the entire body must equal the endogenous glucose production rate; it was similar during control, epinephrine, epinephrine-propranolol, and propranolol insulin clamp studies (Table II) . During the control study, a small increase in total body glucose metabolismn (Table III) (Table II) . During the control insulin clamp study, hepatic glucose production declined promptly to 0.49±0.16 mg/kg min during the first 20 min and remnained suppressed throughout the period ofhyperinsulinemia. In contrast, epinephrine markedly blunted the hepatic response to insulin. During the first 20 min after the initiation of the insulin infusion, a small rise in hepatic glucose production occurred (P < 0.001 vs. control). Thereafter, endogenous glucose production fell progressively, but the percent suppression during the 20-60-min (51 vs. 88%) and 60-120-min (66 vs. 92%) time periods was significantly less than the control's (P < 0.005).
The stimnulatory effect of epinephrine on hepatic glucose production was completely blocked by the simultaneous infusion of propranolol. The infusion of propranolol alone had no effect on the ability of insulin to suppress endogenous glucose produictioni.
Plasmiza amiino acid cf)ncenttrationts. During the control insulin clamp study, a significant decline in the circulating plasma levels of all amino acids, except alanine, was observed. When epinephrine was infuised with insulin, the decline in all plasma amino acids except alanine was potentiated. This was true whether the decrease was expressed on an absolute basis or as the percent decrease from basal (P < 0.02). When propranolol was infuised with epi- nephrine, the potentiating effect was reversed and the decline in plasma amino acid levels was similar to the control insulin clamp study. Propranolol alone had no effect on the plasma amino acid response to hyperinsulinemia.
DISCUSSION
Impaired glucose tolerance after epinephrine infusion could result from decreased insulin secretion or diminished tissue responsiveness to insulin. Although epinephrine has been shown to inhibit insulin secretion in vivo (1-5), a similar inhibitory effect on tissue sensitivity to insulin has not been documented in man.
In the present study we have employed the euglycemic insulin clamp technique in combination with tritiated glucose to quantitate the effect of epinephrine on tissue sensitivity to insulin, and to define the relative contributions of peripheral tissues vs. the liver to the observed insulin resistance. This technique, by maintaining the plasma insulin concentration constant, avoids the epinephrine-induced fall in plasmna insulin that could secondarily result in a decline in glucose metabolism. Also, by clamping the plasma glucose concentration at the basal level, it avoids epinephrineinduced hyperglycemia, which of itself could enhance glucose metabolism and obscure an inhibitory effect of epinephrine.
The present results indicate that the infusion of epinephrine, to achieve plasma levels observed in stress (21) and diabetic ketoacidosis (22) , results in a marked decrease in tissue sensitivity to physiologic hyperinsulinemia. The effect of smaller doses of epinephrine, as might be expected in mild to moderate stress, was not examined in the present study. However, studies by Soman et al. (23) suggest that a similar antagonistic effect would be expected. During the 2-hr study period the total amount of glucose metabolized was significantly reduced in each of the nine subjects by a mean value of 41%. In a previous study we showed that under the present conditions of euglycemic hyperinsulinemia little or no glucose is taken up by the liver (24) . Because with epinephrine the rate of glucose metabolism during the last hour of study was decreased by 3.43 mg/kg min (6.77 to 3.34), a major part of the insulin resistance must reside in peripheral tissues, probably muscle. This observation is consistent with in vitro studies demonstrating an inhibitory action of epinephrine on insulin-mediated glucose metabolism (12) (13) (14) .
Epinephrine also inhibited the ability of hyperinsulinemia to supress hepatic glucose production normally. During the control study, hepatic glucose production declined to 24% of basal within the first 20 min after insulin administration and remained suppressed throughout the remainder of the study. In contrast, epinephrine blocked the inhibitory effect of insulin on hepatic glucose production, and during the first 20 min glucose output actually increased over basal levels. After 20 min, hepatic glucose production began to decline but still remained fourfold higher than during the control insulin clamnp study at the end of the 2-h study period. Several previous reports have shown a stimulatory effect of epinephrine on hepatic glucose production, but the plasma insulin levels in these studies either remnained at basal levels (3) or increased only minimally and transiently (1, 2) as a result of the simultaneous inhibitory effect of epinephrine on insulin secretion. The present study documents that even in the face of persistent hyperinsulinemia (plasma insulin concentration of >100 kLU/ml), stress-associated levels of epinephrine are capable of augmenting hepatic glucose production. Because plasma glucagon fell by 16 pg/ml during the control insulin clamp study, but failed to suppress when epinephrine was infused with insulin, it is possible that part of the lessened effect of insulin on endogenous glucose production is attributable to the higher plasma glucagon levels.
Propranolol, a specific,3-blocker, completely prevented the effects of epinephrine on the liver. The endogenous glucose production rate during the combined infusion of propranolol and epinephrine was not significantly different from the control studies in any time period during the 2 hr of the insulin clamp. Previous in vitro studies employing rat liver (6, 11) have suggested that epinephrine can stimulate hepatic glucose production via both a-and 3-adrenergic receptors. However, the complete blockade of epinephrine-stimulated hepatic glucose production by propranolol in the present study indicates that the hepatic response to epinephrine in man is primarily mediated via the 18-receptor. The difference between the rat and human studies may represent species variation.
Propranolol also completely reversed the effect of epinephrine on insulin-mediated peripheral glucose metabolism. Thus, the rate of glucose metabolism by the entire body during the hour of study increased from 3.34 to 6.78 mg/kg min, a value almost identical to the control study. This observation is consistent with in vitro studies demonstrating that propranolol reverses the epinephrine-mediated inhibition ofglucose metabolism by muscle (12, 14) . Because an a-adrenergic blocking agent was not administered with epinephrine in the present study, the possibility that part of the insulin antagonistic effects is mediated via the aadrenergic receptor cannot be excluded.
In the present study hyperinsulinemia was associated with a significant decline in all plasma amino acids except alanine. The greatest decline was observed for the branch chain amino acids: leucine, isoleucine, and valine. When epinephrine was administered in conjunction with insulin, the fall in all circulating 720 D. C. Deibert and R. A. DeFronzo amino acids except alanine was -15-20% greater than when observed with insulin alone. Again, 8-blockade with propranolol completely reversed the amino acid lowering effect of epinephrine. These results are consistent with previous in vitro studies in rat epitrochlearis muscle, demonstrating that epinephrine, acting through a 8-adrenergic receptor, is a potent inhibitor of amino acid release from muscle (25) . Thus, the effect of epinephrine on both glucose and amino acid metabolism appears to be exerted through the /3-adrenergic receptor.
As compared with epinephrine infusion alone, an interesting feature of the present investigation was the twofold greater rise in plasma epinephrine levels observed when propranolol was infused with epinephrinie. This suggests that propranolol, in some way, interferes with the degradation of epinephrine or causes its displacement from receptor sites. The interpretation of the present results would not be altered by this observation, however, because propranolol comipletely reversed the effects of epinephrine on all metabolic parameters measured despite the much higher circulating epinephrine levels.
